Login / Signup

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.

Petros ChristopoulosFarastuk BozorgmehrLena BrücknerInn ChungJohannes KrisamMarc A SchneiderAlbrecht StenzingerRegina EickhoffDaniel W MuellerMichael Thomas
Published in: BMC cancer (2021)
Clinicaltrials.gov , NCT04318938. Registered March 182,020, https://www.clinicaltrials.gov/ct2/show/NCT04318938 Eudra-CT, 2019-001828-36. Registered September 302,019, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001828-36.
Keyphrases